N,N-二甲基-2-十六烷胺N-氧化物 | 71662-64-1

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: N,N-二甲基-2-十六烷胺N-氧化物
• 英文名称: N,N-dimethylhexadecan-2-amine oxide
• CAS: 71662-64-1
• 化学式: C18H39NO
• 分子量: 285.5
• InChiKey: YTMRCGDXXPVCNT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.4
• 重原子数：
  20
• 可旋转键数：
  14
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  18.1
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• Olanzapine containing transdermal drug delivery compositions
  申请人：Gordon D. Ryan

  公开号：US20070148218A1

  公开（公告）日：2007-06-28

  The invention features compositions for the transdermal administration of olanzapine. The compositions include olanzapine or a pharmaceutically acceptable salt thereof, a pressure sensitive adhesive, and an excipient, such as a permeation enhancer and/or a solubilizer of olanzapine. The compositions are useful for the treatment of certain psychiatric disorders, for example schizophrenia and bipolar mania.

  该发明涉及用于经皮给药奥氮平的组合物。该组合物包括奥氮平或其药学上可接受的盐、一种压敏粘合剂和一种辅料，例如奥氮平的渗透增强剂和/或溶解剂。该组合物对于治疗某些精神障碍，例如精神分裂症和双相障碍，非常有用。
• TRANSDERMAL ADHESIVE COMPOSITIONS, DEVICES AND METHODS
  申请人：Dizio James P.

  公开号：US20130122079A1

  公开（公告）日：2013-05-16

  A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.

  提供一种稳定的经皮粘合剂组合物，包括：一种粘合剂，其包括至少两种乙烯基不饱和单体的洗涤聚合反应产物；以及至少一种易于氧化降解的药物活性化合物；其中，如果至少两种乙烯基不饱和单体以未反应单体的形式存在于粘合剂中，则其存在量不超过总未反应单体的200 ppm，基于粘合剂的总重量；提供制备该组合物的方法，使用该组合物的经皮给药装置，制备该装置的方法，以及给药药物活性化合物的方法。
• Transdermal adhesive compositions, devices and methods
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US10034840B2

  公开（公告）日：2018-07-31

  A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.

  一种稳定的透皮粘合剂组合物，包括 一种粘合剂，包含至少两种乙烯基不饱和单体的洗聚合反应产物；和 至少一种易氧化降解的药用活性化合物； 其中，如果至少两种乙烯基不饱和单体作为未反应单体存在于粘合剂中，则根据粘合剂的总重量，未反应单体总量的含量小于200ppm；提供了组合物的制造方法、使用该组合物的透皮给药装置、装置的制造方法和给药活性化合物的方法。
• Transdermal adhesive compositions, devices, and methods
  申请人：3M INNOVATIVE PROPERTIES COMPANY

  公开号：US10376473B2

  公开（公告）日：2019-08-13

  A stable transdermal adhesive composition comprising: an adhesive comprising a washed polymerization reaction product of at least two ethylenically unsaturated monomers; and at least one pharmaceutically active compound which is susceptible to oxidative degradation; wherein the at least two ethylenically unsaturated monomers, if present in the adhesive as unreacted monomers, are present at a level of less than 200 ppm of total unreacted monomer, based upon the total weight of the adhesive, methods of making the composition, a transdermal drug delivery device using the composition, methods of making the device, and methods of delivery the pharmaceutically active compound are provided.

  一种稳定的透皮粘合剂组合物，包括一种粘合剂，包含至少两种乙烯基不饱和单体的洗聚合反应产物；和 至少一种易氧化降解的药用活性化合物；其中，如果至少两种乙烯基不饱和单体作为未反应单体存在于粘合剂中，则根据粘合剂的总重量，未反应单体总量的含量小于200ppm；提供了组合物的制造方法、使用该组合物的透皮给药装置、装置的制造方法和给药活性化合物的方法。
• Compositions and uses of alpha-adrenergic agents
  申请人：Levation Pharma Ltd.

  公开号：US10828252B2

  公开（公告）日：2020-11-10

  The disclosure provides cosmetic and therapeutic compositions of alpha-adrenergic agents. Compositions of the disclosure may be used for topical, transdermal or parenteral administration to the eye or eyelid. The compositions of the disclosure may be used cosmetically to improve the appearance of the eye or therapeutically to treat ptosis.

  本公开提供了α-肾上腺素能制剂的美容和治疗组合物。本公开的组合物可用于眼部或眼睑的局部、透皮或非肠道给药。本公开的组合物可用于美容，改善眼部外观，或用于治疗上睑下垂。